Advancing Survival in Relapsed/Refractory Multiple Myeloma

A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.

The approval follows a unanimous vote by the FDA’s Oncologic Drugs Advisory Committee where they decided the benefits of cilta-cel outweigh the risks for this patient population.

Idecabtagene vicleucel (ide-cel) demonstrated a 51% reduction in risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the recommended regimens and trials supporting therapies following lenalidomide-refractory relapse of multiple myeloma in the second article of a 2-part series.